Study of 3 Doses of ARD-0403 in Testosterone Deficient Men

• Status: Completed
• Trial end date: 2006-02-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to determine which dose, if any, results in testosterone levels within the normal range for men.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ardana Bioscience Ltd
• Treatments: Methyltestosterone; Testosterone; Testosterone 17 beta-cypionate; Testosterone enanthate; Testosterone undecanoate

Criteria

Inclusion Criteria:

• Testosterone deficiency

• Normal BMI

Exclusion Criteria:

• Previous treatment with testosterone replacement therapy within 4 weeks

• Moderate-severe benign prostatic hypertrophy, or prostatic cancer

• Haematocrit >50%